ReviewJournal of clinical medicine2021
Primary Hyperparathyroidism: A Narrative Review of Diagnosis and Medical Management.
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Quality appraisal of clinical practice guidelines for the evaluation and management of primary hyperparathyroidism.Endocrine · 2024Pooled it
- Efficacy of antiresorptive agents bisphosphonates and denosumab in mitigating hypercalcemia and bone loss in primary hyperparathyroidism: A systematic review and meta-analysis.Frontiers in endocrinology · 2023Pooled it
- Primary hyperparathyroidism presenting as atraumatic bilateral hip fractures: a case report.Journal of medical case reports · 2026Article
- Preoperative Zoledronate Use and Risk of Postoperative Hypocalcemia After Parathyroidectomy for Primary Hyperparathyroidism: A Comparative Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Prevalence and determinants of secondary hyperparathyroidism: IMOS-2021.Scientific reports · 2026Article
- Three Malagasy Cases of Severe Bone Complications Revealing Primary Hyperparathyroidism.Case reports in endocrinology · 2026Article
- Review
- Bone in Parathyroid Diseases Revisited: Evidence From Epidemiological, Surgical and New Drug Outcomes.Endocrine reviews · 2025Review
- Bioanalytical tandem mass spectrometry method for cinacalcet in human plasma: green assessment with advanced metrics.Bioanalysis · 2025Article
- An Analysis of Primary Hyperparathyroidism in Individuals Diagnosed with Multiple Endocrine Neoplasia Type 2.Diseases (Basel, Switzerland) · 2025Review
- An Analysis of Primary Hyperparathyroidism in Association with Depression or Anxiety.Diseases (Basel, Switzerland) · 2025Review
- Article
- Pancreatitis with Intraabdominal Venous Thrombosis as an Initial Presentation of Parathyroid Adenoma: A Rare Clinical Presentation.The American journal of case reports · 2024Article
- Inquiry of the Metabolic Traits in Relationship with Daily Magnesium Intake: Focus on Type 2 Diabetic Population.Clinics and practice · 2024Review
- KMT2A and chronic inflammation as potential drivers of sporadic parathyroid adenoma.Clinical and translational medicine · 2024Article
- [Management of primary hyperparathyroidism with rare localization of ectopic adenoma parathyroid gland].Problemy endokrinologii · 2024Article
- Hyperparathyroidism and Peripheral Arterial Disease.Current vascular pharmacology · 2024Review
- A Case of TKA Failure in Patient with Primary Hyperparathyroidism.Orthopaedic surgery · 2023Article
- Neuroendocrine Parathyroid Tumors: Quality of Life in Patients with Primary Hyperparathyroidism.Biomedicines · 2023Review
- Exploring the Risk Factors and Possible Role of Calcium in Infective Endocarditis.Diagnostics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary hyperparathyroidism (PHPT) is the most common cause of hypercalcemia in the outpatient setting. Symptomatic presentation includes non-specific signs and symptoms of hypercalcemia, skeletal fragility, nephrolithiasis and nephrocalcinosis. The majority of individuals present at an asymptomatic stage following routine biochemical screening, without any signs or symptoms of calcium or parathyroid hormone (PTH) excess or target organ damage. Indications for surgery have recently been revised as published in recent guidelines and consensus statements. Parathyroidectomy is advised in patients younger than 50 years old and in the presence of either significant hypercalcemia, impaired renal function, renal stones or osteoporosis. Surgery is always appropriate in suitable surgical candidates, however, medical management may be considered in those with mild asymptomatic disease, contraindications to surgery or failed previous surgical intervention. We summarized the optimal medical interventions available in the care of PHPT patients not undergoing parathyroidectomy. Calcium and vitamin D intake should be optimized. Antiresorptive therapy may be used for skeletal protection in patients with an increased fracture risk. Cinacalcet, a calcimimetic agent, has been shown to effectively lower serum calcium and PTH levels. The effect of medical treatment on the reduction in fracture risk is unknown and should be the focus of future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.